Skip to main content
  • Home
  •  Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies

Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies

Topic:
  • Structural Heart Disease

Available Credit:

  • 0.50 AMA PRA Credit

Course Published On:

Course Expiry Date:

HCM in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
No ratings

Release / Expiration Date

August 3, 2022 – August 3, 2023

Method of Participation

This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. There is no fee to participate in the activity or for the generation of the certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Radcliffe Medical Education. ACHL is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.

Commercial Support

This activity is supported by an educational grant from Bristol Myers Squibb.

Disclosure

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. 

 

The following financial relationships have been provided:

Grants/Research Support: Pfizer, Ionis, Ultomics
Consultant: Bristol Myers Squibb, Eidos
Honoraria: Alnylam, Eidos, Pfizer

 

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: The use of unlabelled drugs (aficamten and mavacamten) will be discussed. 

Staff and Reviewer Disclosures

ACHL and Radcliffe Medical Education staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Terms & Conditions

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

 

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

 

This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Other Allied Healthcare Professionals

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
  • Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities

Speaker

Ahmad Masri

Oregon Health & Science University Medical Group, Portland, USA

Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.

He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.

View full profile
0.50 AMA PRA Credit

Related Courses

TIO 2023 – Key Issues in TAVI - Live Cases and Discussions
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
TIO 2023 – Key Issues in TAVI
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
TIO 2023 – Symposium: Lifetime Patient Management Greater Expectations: Is TAVI Rising to The Challenge?
  • 1.00 EBAC

Learning objectives

  • Recall the latest data on durability and clinical outcomes for TAVI
  • Understand how TAVI is advancing and become aware of future treatment options for lifetime management of patients with aortic valve disease
  • Become more confident using TAVI in cases with complex anatomy
See more
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER? – Live Cases & Discussions
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
TIO 2023 – Atrioventricular Valve Replacement Beyond TEER?
  • 1.00 EBAC

Learning objectives

  • Compare the utility of repair and replacement valve technology in mitral regurgitation
  • Individualise valve choice for aortic regurgitation based on valve durability and patient features
  • Recall the utility and limitations of specialty balloons
  • Evaluate emerging approaches to the treatment of complex left main and other coronary bifurcation lesions
  • Discuss the impact of PCI on top of optimal medical therapy in ischaemic left ventricular systolic dysfunction
  • Identify suitable patients for interatrial shunting
  • Discuss the merits of alternative antiplatelet strategies to DAPT in ACS and CCS following PCI
See more
HCM in Review: Highlights of 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
See more
HCM in Review: Assessing SCD Risk in HCM & Managing HCM With High Risk SCD
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall risk factors associated with sudden cardiac death (SCD)
  • Recall best practice approaches to prevent SCD according to guidelines and expert insight
  • Stratify patients likely to benefit from invasive procedures versus pharmacological treatment
See more
Severe Aortic Stenosis: Stratifying Patients for Lifetime Management
  • 1.00 EBAC

Learning objectives

  • Describe the challenges with lifetime management in severe AS in both a SAVR and TAVI-first scenario
  • Summarise clinical evidence for TAVI in low surgical risk patients
  • Recall different guideline recommendations for SAVR and TAVI approaches
  • Assimilate current clinical knowledge with patient preferences when formulating treatment plans for severe AS patient
See more
HCM in Review: Highlights of ACC 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
See more
Getting it Right First Time in Severe Aortic Stenosis - Key insights for Long Term Success
  • 1.00 EBAC

Learning objectives

  • Recall current and predicted trends in TAVI with respect to preserving coronary access
  • Consider determining factors for choosing valves in low risk populations
  • Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
See more